Peter Bach, MD, Director of the Center for Health Policy & Outcomes, Memorial Sloan Kettering

Dr. Bach’s main research interests cover healthcare policy, particularly as relates to Medicare, racial disparities in cancer care quality, and lung cancer epidemiology.

His research examining quality of care for Medicare beneficiaries has demonstrated that blacks do not receive as high quality care as whites when diagnosed with lung cancer, and that the aptitude and resources of primary care physicians who treat blacks are inferior, when compared to primary care physicians who primarily treat whites.

In 2007 he was the senior author on a study demonstrating that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists.

His work in lung cancer epidemiology has focused on the development and utilization of lung cancer prediction models that can be used to determine what lung cancer events populations of elderly smokers will experience over a period of time. His healthcare policy analysis includes investigations into Medicare’s approaches to cancer payment, as well as developing models of alternative reimbursement, payment systems, and coverage policies.

He is funded by grants from the National Institute of Aging, a contract from the NCI, and philanthropic sources. He formerly served a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He serves on several national committees, including the Institute of Medicine’s National Cancer Policy Forum, and the Committee on Performance Measurement of the National Committee on Quality Assurance. He chairs the Technical Expert Panel that is developing measures of cancer care quality for CMS. Along with publishing in the medical literature, Dr. Bach’s opinion pieces have appeared in numerous lay new outlets, including the New York Times, the Wall Street Journal, Forbes Online and National Public Radio.

Jack Bailey, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKline

Jack Bailey is Senior Vice President, Policy, Payers and Vaccines at GlaxoSmithKline. In this role, Jack leads Government Relations, Public Policy, Payer Marketing, National and Regional Accounts, Channel Development & Sales and Contract Management Operations for GSK in the United States. His organization ensures that GSK takes a holistic approach to health care policy and its impact on funding and reimbursement decisions in the United States. In addition, Jack is responsible for Puerto Rico operations and GSK’s US Vaccines Business Unit.

Jack joined GSK in May 2009 following a successful eighteen-year career with Eli Lilly, where he most recently serving as Senior Vice President, Account-based Markets Division. Jack had a series of roles of increasing importance while with Lilly, including general manager for Eli Lilly South Africa and later Area Director for the Sub-Saharan region.

Jack currently serves as First Vice Chair of the Board of Directors for the North Carolina Chamber of Commerce. Additionally, Jack services on the boards of the National Pharmaceutical Council Executive Committee, the Joint Commission Resources and the Triangle Global Health Consortium. In March of 2012, the University of North Carolina at Chapel Hill Kenan-Flagler Business School presented him with the Distinguished Alumni Award in recognition of his efforts and passion for recruiting key talent.

Jack received his BS in biology with a concentration in genetics from Hobart College, Geneva, New York and his MBA from the University of North Carolina at Chapel Hill Kenan-Flagler Business School.

Josh Benner, PharmD, ScD, CEO, RxAnte

Josh Benner is the President and CEO of RxAnte, a provider of science-based information technology solutions for improving quality and lowering the cost of health care. The RxAnte Solution™ helps health care organizations improve medication adherence objectively and efficiently by applying proprietary predictive analytics and decision analytics to ensure the right patient gets the right intervention at the right time. The company’s analytic technology was previously incubated at Crimson Health, LLC.

A leading voice on medication adherence, Dr. Benner’s award-winning research and numerous publications have shed new light on the problem of nonadherence and identified promising approaches to improving it. Prior to RxAnte, Dr. Benner was Fellow and Managing Director at the Brookings Institution’s Engelberg Center for Health Care Reform, where he focused on medical technology policy. Prior to Brookings, Dr. Benner was principal at ValueMedics Research, an analytic and consulting services firm. Following the successful sale of ValueMedics to IMS Health in 2007, he served as senior principal in health economics and outcomes research and global lead for medication adherence at IMS. Dr. Benner received his Doctor of Pharmacy degree from Drake University and his Doctor of Science in health policy and management from the Harvard University School of Public Health. He remains a Visiting Scholar in Economic Studies at Brookings, and is an adjunct scholar in Clinical Epidemiology and Biostatistics at the University of Pennsylvania School of Medicine.

Jeff Berkowitz, Senior Vice President, Pharmaceutical Development and Market Access, Walgreen Co.

Jeff Berkowitz is the Senior Vice President, Pharmaceutical Development and Market Access at Walgreen Co. In this role, Jeff leads Walgreen’s pharmaceutical procurement and supply chain, pricing and contracting and managed markets sales and marketing for all of Walgreens diverse capabilities. He is responsible for enterprise-wide purchasing and inventory management of $40+ Billion brand, generic and specialty pharmaceuticals for retail, mail, specialty and home care pharmacies. Prior to joining Walgreens in September 2010, Mr. Berkowitz was senior vice president of global market access for Merck & Company, Inc.

Kim Caldwell, Director, Pharmacy, Professional Affairs (previously Director, Competitive Health Analytics) Humana

Kim Caldwell is employed by Humana Inc. as Director, Pharmacy Professional Affairs, previously Director, Competitive Health Analytics (CHA), the outcomes research group powered by Humana Pharmacy Solutions (HPS). Additionally, he is the HPS business owner for pharmacy related health information technology projects including electronic prescribing. During 2004-2005, Kim served the Centers for Medicare and Medicaid Services (CMS) as Division Director – Clinical and Economic Performance in the Center for Beneficiary Choices (CBC). As one of two outside, non-government directors asked to join the Medicare Drug Benefit Group, Mr. Caldwell helped lead the development and implementation of Part D – the Medicare prescription drug benefit that began on January 1, 2006. Among other duties, his division was responsible for the first level oversight for much of the drug benefit including performance measures, utilization management and measures, quality, safety, medication therapy management, drug trend analysis, cost trend analysis, Part D electronic prescribing, complaints, grievances, and coverage determinations including exceptions and appeals. In addition, he was instrumental in the development of the CMS data warehouse and analytics strategy that will lead to future post-marketing studies and determinations.

Jack Challis, CEO & Co-Founder, CliniCast

Jack Challis is the co-founder and CEO of CliniCast, a healthcare analytics company empowering providers to make smarter decisions leading to better outcomes and lower costs. Before founding CliniCast, he was a product development scientist for the Archimedes IndiGO tool, helping physicians assess and optimize cardiovascular disease. Jack has a Physics PhD from Yale University.

William Fera, MD, Principal, Ernst & Young

Dr. Fera is a Principal in the Advisory Services practice and serves as the Clinical Transformation leader for Health Care clients. He has provided over a decade of clinical and information technology leadership at academic, community and ambulatory medical centers and has consistently worked to redefine the model of healthcare delivery through deployment of state-of-the-art information technologies to produce superb clinical and financial outcomes.

Dr. Fera’s professional background includes serving as a member of the UPMC Quality Patient Care Board, as well as the Clinical Quality Improvement committee for the UPMC Health Plan. Through these efforts, Dr. Fera has gained a unique understanding of the challenges facing health care organizations from a payer and provider system level and endeavors to find and promote technologies to further the mission of patient care.

Dr. Fera is a graduate of the Medical College of Pennsylvania with Alpha Omega Alpha honors, and served as chief resident at University of Pittsburgh Medical Center, St. Margaret Hospital. Dr. Fera has bachelor degrees from the University of Pennsylvania and Wharton School of Business.

Jay Galeota, President, Hospital and Specialty Care Merck & Co.

Jay Galeota is president of the hospital and specialty care customer business line for Merck Global Human Health (GHH), which includes immunology, oncology, hepatitis, HIV, neuroscience, ophthalmology, antibiotic, antifungal, thrombosis, anesthetic and antiarrhythmic products. The hospital and specialty care business represents close to $11 billion in worldwide revenues for Merck.

Previously, Mr. Galeota served as senior vice president of GHH strategy and business development, and he continues to lead this group. Strategy and business development is responsible for identifying new models and business development opportunities that broaden the GHH portfolio and establish leadership in Merck’s franchises and markets.

Since joining Merck in 1988 as a sales representative, Mr. Galeota has assumed a variety of U.S. and global roles with increasing leadership responsibility. In Merck’s U.S. division, he managed promotion of the anti-ulcer drug PRILOSEC and VASOTEC for high blood pressure. He also served as product manager for ZOCOR and marketing director and senior director in Merck’s osteoporosis business group during the launch of FOSAMAX.

As U.S. senior business director, Mr. Galeota led Merck’s highest revenue U.S. sales region. He later assumed roles as vice president of worldwide marketing for the atherosclerosis and diabetes franchise; general manager of the global commercialization team for JANUVIA, where he led the launches of JANUVIA and JANUMET; and senior vice president and general manager of the diabetes and obesity franchise. After the merger of Merck and Schering-Plough in 2009, Mr. Galeota led the integration of the global pharmaceutical and vaccine businesses.

Mr. Galeota holds a Bachelor of Science degree in biology from Villanova University and is a graduate of Harvard Business School’s Advanced Management Program. He currently serves on the boards of Solaris Health System, Inc., Global Health Innovation Fund LLC, the New Jersey Symphony Orchestra, and the Metuchen Edison Woodbridge YMCA.

Mr. Galeota is married and has three children. In addition to business, his interests include sailing, skiing, flying, automobiles and music.

Robert Galvin, MD, CEO, Equity Healthcare

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms owned by private equity companies. The focus is on using purchasing power to create innovative ways to achieve higher value health care, through improved population health, clinical quality and delivery system reforms. Currently, EH encompasses over 30 companies with healthcare spending exceeding $1.2B annually.

Before joining Blackstone, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric (GE) for fifteen years, where he was in charge of the design, financial and clinical performance of GE’s health programs. He was also responsible for health policy strategies affecting employees. Dr. Galvin is a nationally recognized leader in the areas of market-based health policy and financing, quality measurement and payment reform. His work has been widely published in the New England Journal of Medicine and Health Affairs and he was a co-founder of the Leapfrog Group and founder of two other groups, Bridges to Excellence and Catalyzing Payment Reform, all innovative non-profits that have helped drive the quality agenda.

Dr. Galvin is a member of the Institute of Medicine, a branch of the National Academy of Science, and sits on the IOM’s Board on Health Care Services. He is also on the Board of Vanguard Health Systems and the non-profit National Quality Forum. Dr. Galvin is Professor Adjunct of Medicine and Health Policy at Yale. His work has received awards from the National Business Group on Health, the Healthcare Financial Management Association and the National Coalition for Cancer Survivorship. He is a fellow of the American College of Physicians.

Glen Giovannetti, Global Life Sciences Leader, Ernst & Young

Glen is Ernst & Young’s Global Life Sciences Sector Leader. Glen has over 28 years of experience with Ernst & Young, the majority serving clients in the biotechnology and medical device industries. He has extensive experience in assisting clients with strategic transactions including equity and debt offerings, technology licensing and R&D collaborations, joint ventures and acquisitions.

Glen leads a team focused on understanding the evolving needs of clients in the life sciences industry, monitoring trends and business drivers, and networking and informing Ernst & Young professionals serving the life sciences industry globally. The team is also responsible for producing Ernst & Young Thought Leadership publications on the industry including the annual reports Progressions (Life Sciences), Beyond Borders (Biotechnology, now in its 25th year) and Pulse of the Industry (Medtech). Glen is a frequent speaker at life sciences industry events around the globe.

Prior to assuming his present role, Glen was a partner in the firm’s Silicon Valley practice and also spent three years in the firm’s Milan, Italy office. He is a member of the board of directors of the Biotechnology Industry Organization, chairs New England Funding a Cure, an event that raises money for early cancer research, and is a member of the Leadership Council of The Schwartz Center for Compassionate Care at Massachusetts General Hospital.

Rhonda Greenapple, President, Reimbursement Intelligence

Rhonda has spent her 20-year career focused on how to gain access and reimbursement for her clients, helping with launch planning and commercialization for over 40 products, with particular experience in diabetes, obesity, cardiometabolic risk and oncology. Prior to founding Reimbursement Intelligence in 2005, Rhonda was President of Torre Lazur McCann Managed Markets, a unit of McCann Healthcare Worldwide. She is also a frequent contributor on reimbursement trends to publications such as Managed Care Magazine, American Health and Drug Benefits,, Oncology News International and Journal of Medical Marketing and Fierce Pharma Industry Voices. Rhonda received her BS from Cornell University and received her MS in Public Health from the University of North Carolina.

Volker Herrmann, MD, VP and Global Business Leader, Integrated Health Business, Pfizer

Volker Herrmann, MD is Vice President and Global Business Leader of the Integrated Health Business at Pfizer. As the healthcare environment continues to evolve globally, Integrated Health is focused on building the leading service and solution offering that improves outcomes for patients while reducing costs for payers, employers and providers through prevention, diagnosis and treatment optimization and disease reversal solutions. Integrated Health builds on Pfizer’s strong foundational capabilities and expertise in disease areas such as pain, cardiovascular disease, Diabetes and general wellness.

Before taking on this role, Volker was Vice President of Marketing for CNS/Pain in Europe/Canada starting in 2006 and became a member of the Primary Care Leadership team responsible for Europe, Canada, Australia and New Zealand in 2008. Volker joined Warner Lambert in 1999 and has held a variety of medical, marketing and sales management roles in the German Pfizer organization before transitioning into his European responsibility.

Volker holds a medical degree and PhD in Pharmacology from the University of Freiburg and was trained in cardiology and clinical pharmacology at the University of Mainz and University of California, San Diego. He also received a MBA from the University of San Diego.

Annalisa Jenkins, EVP Head of Global Development and Medical, Merck Serono

Annalisa Jenkins, MBBS, MRCP, is Executive Vice President, Head of Global Drug Development and Medical for Merck Serono. Dr. Jenkins is also a member of the Pharmaceutical Executive Committee.

Prior to joining Merck Serono, Dr. Jenkins was Senior Vice President, Global Medical Affairs at Bristol-Myers Squibb (BMS). She started with BMS in 1997 as a Cardiovascular Medical Advisor based in the UK. In 2000, she moved to Australia to serve as Executive Medical Director for Australia and New Zealand, subsequently leading the Medical Division across Asia Pacific and Latin America.

In 2002, Dr. Jenkins moved to BMS’s major R&D site in Princeton, New Jersey, to oversee the company’s International Medical Division. After three years in this role, she was appointed Chief Medical Officer (CMO) for Europe, Middle East and Africa, subsequently taking on the position of Senior Vice President and CMO responsible for the Americas and the Development Teams.

Annalisa Jenkins began her career as a Medical Officer with the British Royal Navy, and served with the Minesweeper Squadron during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. She graduated in Medicine from St Bartholomew’s Hospital London and trained in Cardiology with the UK National Health Service.

Clifford Jones, CEO of Allazo Health

Clifford is the CEO of Allazo Health, a firm that uses predictive analytics to better solve the problem of medication non-adherence for health insurers, PBMs, ACOs, and integrated delivery networks. Allazo Health’s proprietary AllazoEngineTM predicts which patients will be non-adherent to each of their medications and also predicts what interventions will best influence each of those patients to take their medication.

Previously Clifford developed CVS Caremark’s award-winning “Pharmacy Advisor” medication adherence program, which earned the “2011 Rx Benefit Innovation Award” from the Pharmacy Benefit Management Institute and a “Best Practices in Health Care Consumer Protection and Empowerment Award” from URAC. Earlier in his career, Clifford led the development of analytics software for the Boston Consulting Group.

Clifford graduated from the University of Pennsylvania’s dual-degree Management and Technology program where he studied management, engineering and mathematics. He also studied at Wharton in the Health Care Management MBA program.

Alex Jung, Principal, Ernst & Young

Alex Jung is a Principal in the Advisory Services practice of Ernst & Young. Prior to joining EY, she was the Senior Vice President of Walgreens Corporate Strategy division based in Deerfield, IL. Mrs. Jung has over 25 years of experience with healthcare and employee benefits strategy and consulting. She began her career at Arthur Andersen where she led various healthcare businesses over ten years, went on to lead the National Health Care Analysis Unit for William M. Mercer and then spent numerous years as the healthcare practice leader at AonHewitt prior to joining Walgreens. She joined E&Y in 2012.

Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Office of the CMO, Aetna

Michael Kolodziej M.D. is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University Of Oklahoma School Of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He has published several manuscripts and given several presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost of care in oncology. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology.

Thomas Kottler, CEO, HealthPrize Technologies

Tom Kottler is the CEO and Co-Founder of HealthPrize Technologies, a company that has developed an Internet and mobile-based platform that uses gaming dynamics, behavioral economics and proven concepts from consumer marketing to motivate patients to start and stay on their prescribed medications.

HealthPrize is the fourth start-up venture that Tom has founded or been associated with as part of the initial management team. His first start-up, MedAptus, a healthcare IT company in Boston, is still going strong 12 years later. Celadon Science, now Advanced BioHealing (acquired by Shire in May 2011 for $750M), develops and markets cell-based wound care technology. VeinAid develops non-invasive technology to treat varicose veins, based on patents with Tom as a named inventor.

Prior to his entrepreneurial career, Tom was on the management team of a mid-sized CRO that conducted trials for pharmaceutical companies. He helped manage the growth and sale of that company to a Fortune 500 company, for one of the highest multiples ever paid for a privately held CRO. Prior to that, Tom practiced law for nine years in Chicago and Connecticut, doing litigation and corporate law. He received his undergraduate degree from Middlebury College and his law degree from The George Washington University.

Ellen Licking, Senior Analyst, Real Endpoints

Ellen has covered the medical industry for more than 10 years, as a reporter at BusinessWeek, then at Windhover Information, and since it’s acquisition by Elsevier, as business bureau chief and executive editor for the pharma group, where she has been responsible for both IN VIVO and Start-Up, among other duties. Ellen holds a BA in Biochemistry from Swarthmore College, an M. Phil. in Biochemistry from Cambridge University, and an MS in Biochemistry from Stanford University.

Roger Longman, CEO, Real Endpoints

Roger Longman has spent nearly thirty years in the healthcare industry, most recently as Managing Director, Pharma at Elsevier Business Intelligence, a Reed Elsevier company. In 1983, Longman joined The Wilkerson Group as a writer covering the pharmaceutical and biotech industries for IN VIVO. In 1989, Longman along with David Cassak bought IN VIVO, incorporating it into a new company, Windhover Information, which they built through internal development (with publications such as Start-Up and The RPM Report, several databases, including The Strategic Transactions Database; and a series of senior-executive conferences), and through acquisition.

Dr. Lynn Marks, SVP, Projects, Clinical Platforms & Sciences Pharmaceuticals R&D, GlaxoSmithKline

Dr. Marks currently has operational accountability for clinical trials over a broad range of disease and therapeutic areas on a global scale ranging across the Phase I to IV development landscape. Additionally he has responsibility for business support functions such as performance metrics, clinical systems support, clinical trial contracting, outsourcing strategy & implementation and GCP, as well as, core training across R&D. Further, his remit includes key capabilities such as Project Management, Study & Data Management, clinical trial Monitoring, Programming and Statistics (preclinical and clinical). Areas of analytics and modeling are included through the Genetics, Computational Biology, PK/PD modeling and Epidemiology teams. He also leads the Simplifying Clinical Development Change Initiative which focuses on increasing productivity across R&D by bringing together a focus on behaviors, processes, standards and technology. This has expanded to include a collaborative effort across 10 Pharma companies in a newly formed TransCelerate BioPharma, not-for-profit entity. He provides scientific and technical input to the Scientific Review Board governance body as well as membership on the R&D Leadership team.

He joined the company in 1993 working in the Infectious Diseases Clinical organization with increasing levels of accountability. He then transferred to the Consumer Healthcare R&D team to lead an Rx to OTC switch initiative and subsequently became head of Consumer Health Medical and Regulatory Worldwide. Next he returned to Pharma R&D as head of the Infectious Diseases Therapy area based in the UK. Over the next 10 years, he had the opportunity to grow and learn from varying organizational changes with resultant shifts in accountability as head of the Infectious Diseases Development group, and returned to be based in the US. Subsequently, he transitioned to lead the Center for Project and Study Excellence in 2008 which has now expanded to become the Projects, Clinical Platforms & Sciences team.

Dr. Marks is Board Certified in Internal Medicine and Infectious Diseases. Before joining GSK, he was on faculty at the University of South Alabama Medical Center with joint appointments in Infectious Diseases, Microbiology and Pharmacology. In addition to teaching and patient care responsibilities, he led a NIH grant funded research lab focused on the molecular genetics of bacterial pathogenicity.

Douglas J. Moeller, MD, Medical Director, McKesson Health Solutions

Douglas J. Moeller, MD, has been a Medical Director with McKesson Health Solutions in the Claims Performance Group for the past nine years. His primary accountability involves the clinical integrity of KnowledgeBase development for McKesson claims auditing and advanced diagnostics management solutions. In addition, Dr. Moeller has major responsibilities in customer support, special projects, and new product development. He has been actively involved in the coding and reimbursement challenges for molecular diagnostic testing for more than 6 years – in particular the need for unique identifiers for each and every unique test.

Dr Moeller is a Board-certified General Internist; he was actively in private medical practice before transitioning to full-time duties in medical group management, managed care administration and, now, medical informatics.

Clayton Nicholas, Vice President, Marketing and Strategy, Change Healthcare

Clayton Nicholas brings nearly two decades of experience as an entrepreneur, Fortune 50 executive and Army Officer to his role with Change Healthcare. After honing his expertise in general management, marketing, strategy and sales techniques across healthcare and information technology sectors, he now leads marketing and public relations functions while helping drive strategy and innovation. Most recently, Nicholas was executive director of clinical strategy and operations for Walgreens. Previously, he founded and sold incentives company Giving Tree, LLC and led marketing, strategy and sales functions at Healthways and IBM. He began his career as a medical specialist and Signal Corps Officer in the U.S. Army, leading soldiers in deployments to Bosnia and Kosovo, and exiting service as a Captain.

Nicholas holds a bachelor’s degree in engineering management from the United States Military Academy at West Point, a master’s degree in information systems from the University of Maryland and a master’s degree in business administration from Harvard Business School.

Kristin Pothier, Partner, Health Advances

Kristin leads the Diagnostics and Life Sciences Practice at Health Advances, a global practice which combines her consulting and scientific experience to provide results-oriented commercialization strategies for her clients in the pharmaceutical, life sciences, and clinical diagnostics sectors, including focus on launch strategy, pricing, and R&D prioritization for novel products for the research laboratory, personalized medicine, point-of-care, and mainstream clinical diagnostics. Kristin is a noted speaker, workshop leader and writer in the diagnostics and life sciences industries, covering topics such as the future of point-of-care platforms, the commercialization of companion diagnostics, and innovations in personalized medicine. Most recently, she worked with MassBio to develop its Personalized Medicine Year, is on the organizing committee for the Harvard Personalized Medicine Conference, was a judge for the Coulter Translational Research Awards, and is working with BIO to promote reimbursement reform for personalized medicine products. She is also a co-founder of DxInsights, an independent organization designed to educate on the impact of diagnostics in improving health care outcomes to the nation’s healthcare communities.

Kristin has over 16 years of experience in the diagnostics and drug discovery industries. Prior to joining Health Advances in 2002, Kristin was a scientist in diagnostics technology development at Genzyme and genomics research at Genome Therapeutics. She has an undergraduate degree in Biochemistry from Smith College and a Masters degree in Epidemiology, Health Management, and Maternal and Child Health from the Harvard School of Public Health.

Ammar Qadan, Global Commercial Lead: Interferon Lambda Hepatitis-B Program, Bristol-Myers Squibb

A Pharmaceutical industry expert trained with broad experience in sales, marketing, market access, Country/General management, strategy development, commercial operations with significant experience across different geographies & cultures.

During his 21+ years with BMS Ammar has held the following positions: Executive Director- Diabetes Payer Marketing US; Market Access Lead (All Therapeutic Areas)- Intercontinental Region ( All geographies outside US & Europe); Director of Plavix Commercialization Europe; Associate Director of Plavix Commercialization Europe; Country Manager Eastern Mediterranean; Marketing & Sales Roles in various geographies.

Ammar received his degree – Pharm.D – from University of Jordan.

Jon Resnick, VP RWE Solutions, IMS Health

Jon Resnick is a Vice President within IMS’ Healthcare Value Solutions business, responsible for global Real-World Evidence (RWE) Solutions and Health Economics and Outcomes Research. The RWE business, comprised of more than 200 professionals in 14 countries, focuses on the development and application of information, technology and analytics to meet the evidence needs of payers, regulators and other scientific and commercial stakeholders.

Jon joined IMS’ management consulting business in 2002, where he advised pharmaceutical and biotechnology clients on corporate, organizational and product strategy. Since 2006, Jon has held several leadership positions within IMS, including Regional Leader for the IMS Consulting Group in Europe and Practice Leader for IMS’ EMEA Pricing and Market Access business.

Prior to joining IMS, Jon served as Professional Health and Social Security Staff for the United States Senate Committee on Finance in Washington D.C.

Jon holds a BA in Political Science from Union College (NY) and an MBA from the Kellogg School of Management, Northwestern University.

Lewis G. Sandy, MD, FACP, SVP, Clinical Advancement, UnitedHealth Group and Principal, UnitedHealth Center for Reform and Modernization

Lewis G. Sandy, M.D., is Senior Vice President, Clinical Advancement, UnitedHealth Group (a Fortune 25 diversified health and well-being company dedicated to helping people live healthier lives). At UnitedHealth Group he leads efforts to promote efficient and effective health care, provide tools and information to doctors and patients to promote health, advance productive partnerships and collaborations among physicians and medical/specialty societies, and foster the growth of evidence-based medicine. He also is a Principal in the UnitedHealth Center for Health Reform and Modernization, with a focus on payment/delivery innovation and policy.

Dr. Sandy joined UnitedHealthcare in March, 2003. From 2003 to 2007, he was EVP and Chief Medical Officer of UnitedHealthcare, UnitedHealth Group’s largest business focusing on the employer/individual health benefits market. From 1997 to 2003, he was EVP of The Robert Wood Johnson Foundation (RWJF), the nation’s largest health-focused private foundation. At RWJF, he was responsible for the Foundation’s program development and management, strategic planning and administrative operations. Prior to this, Sandy was a program VP of the Foundation, focusing on the Foundation’s workforce, health policy, and chronic care initiatives. An internist and former health center medical director at the Harvard Community Health Plan in Boston, Massachusetts, Sandy received his B.S. and M.D. degrees from the University of Michigan and an M.B.A. degree from Stanford University. A former RWJF Clinical Scholar and Clinical Fellow in Medicine at the University of California, San Francisco, Sandy served his internship and residency at the Beth Israel Hospital in Boston. He is a Senior Fellow of the University of Minnesota School of Public Health, Department of Health Policy and Management.

Joe Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute

Joe V. Selby, M.D., M.P.H., is the first Executive Director of the Patient-Centered Outcomes Research Institute (PCORI). A family physician, clinical epidemiologist and health services researcher, he has more than 35 years of experience in patient care, research and administration. He will identify strategic issues and opportunities for PCORI and implement and administer programs authorized by the PCORI Board of Governors.

Building on the work of the Board and interim staff, Selby will lead the organizational development of PCORI, which was established by Congress through the 2010 Patient Protection and Affordable Care Act. In addition to creating an organizational structure to carry out a national research agenda, Selby will lead PCORI’s external communications, including work to establish effective two-way communication channels with the public and stakeholders about PCORI’s work.

Selby joined PCORI from Kaiser Permanente, Northern California, where he was Director of the Division of Research for 13 years and oversaw a department of more than 50 investigators and 500 research staff working on more than 250 ongoing studies. He was with Kaiser Permanente for 27 years. An accomplished researcher, Selby has authored more than 200 peer-reviewed articles and continues to conduct research, primarily in the areas of diabetes outcomes and quality improvement. His publications cover a spectrum of topics, including effectiveness studies of colorectal cancer screening strategies; treatment effectiveness, population management and disparities in diabetes mellitus; primary care delivery and quality measurement.

Selby was elected to membership in the Institute of Medicine in 2009 and was a member of the Agency for Healthcare Research and Quality study section for Health Care Quality and Effectiveness from 1999- 2003. A native of Fulton, Missouri, Selby received his medical degree from Northwestern University and his master’s in public health from the University of California, Berkeley. He was a commissioned officer in the Public Health Service from 1976-1983 and received the Commissioned Officer’s Award in 1981.

He serves as Lecturer in the Department of Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, and as a Consulting Professor, Health Research and Policy, Stanford University School of Medicine.
Selby was appointed PCORI executive director on May 16, 2011, and formally begins his duties on July 1, 2011.

Michael Sherman, MD, SVP & Chief Medical Officer, Harvard Pilgrim

Dr. Michael Sherman is the chief medical officer and senior vice president of Harvard Pilgrim Health Care, a nationally recognized not-for-profit health plan that provides a variety of insurance options to more than one million members in Massachusetts, New Hampshire and Maine.

Dr. Sherman is responsible for Harvard Pilgrim’s clinical departments, provider engagement strategy, medical informatics, health promotion initiatives, outreach and disease management services, pharmacy services, NCQA accreditation and quality and utilization programs.

Dr. Sherman received his M.D. from Yale, M.B.A. from the Harvard Business School and M.S. from the University of Pennsylvania. He currently serves on the faculty of Harvard Medical School.

Jean Slutsky, PA, MSPH, Director of the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services

Jean R. Slutsky, P.A., M.S.P.H., has directed the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services since June 2003. Prior to Ms. Slutsky’s appointment as director of COE, she served as acting director of the Center for Practice and Technology Assessment at AHRQ. Ms. Slutsky oversees the Evidence-based Practice Center program; Technology Assessment Program; extramural and intramural research portfolios concerning translating research into practice, outcomes and effectiveness research, including pharmaceutical outcomes, and cost-effectiveness analyses; and the National Guideline, Quality Measures, and QualityTools Clearinghouses.

Prior to becoming acting director of the Center for Practice and Technology Assessment, Ms. Slutsky directed the development of the National Guideline Clearinghouse™ (NGC) Project. The NGC is an Internet-based repository (www.guideline.gov) for comparative information on evidence-based clinical practice guidelines. In addition, Ms. Slutsky served as project director of the U.S. Preventive Services Task Force, an internationally recognized panel of experts who make evidence-based recommendations on clinical preventive services. Ms. Slutsky is a member of the Executive Board of the Guidelines International Network.

Ms. Slutsky received her Bachelor of Science degree at the University of Iowa, a Masters of Science in Public Health (Health Policy and Administration) from the University of North Carolina at Chapel Hill, and trained as a Physician Assistant at the University of Southern California.

Ted Snelgrove, Chief Commercial Officer, Crescendo Bioscience

Mr. Snelgrove brings to Crescendo Bioscience nearly 20 years of experience launching complex products in the healthcare field. As Vice President, Sales & Marketing for Genomic Health, he was responsible for commercialization of the Oncotype DX® Breast Cancer Assay. Prior to that, he worked for several leading biopharmaceutical companies, including ALZA, Amgen, Immunex and Eli Lilly, serving in a range of commercial positions from Sales to Marketing to Business Development. Mr. Snelgrove’s professional career started as an officer with the U.S. Navy, where he flew helicopters and managed officer recruiting. He received an MBA in Marketing from the University of Michigan.

John Sprandio, MD, FACP, Lead Physician, Consultants in Medical Oncology & Hematology, P.C.,
President, Oncology Management Services, LLC.

John D. Sprandio, M.D., F.A.C.P is Chief of Medical Oncology and Hematology at Delaware County Memorial Hospital, where he also serves as Director of the Delaware County Regional Cancer, a member of the Fox Chase Network, Director of the Medical Oncology QA Program and Chairman of the Department of Medicine.

Board certified in Internal Medicine, Medical Oncology and Hematology, Dr. Sprandio received his Medical Degree from Temple University School of Medicine, completed his Residency training at Pennsylvania Hospital and Fellowship in Medical Oncology and Hematology at Thomas Jefferson University Hospital. From 1998 to 2000, he served as President of the Medical Staff at DCMH and in addition to various administrative appointments, he maintains a private practice, Consultants in Medical Oncology and Hematology, P.C in Delaware County, Pennsylania. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Society of Hematology. As Lead Physician for Consultants in Medical Oncology and Hematology, P.C., his practice received the first Oncology Patient Centered Medical Home Level III recognition in the country on April 30, 2010. He is the President of Oncology Management Services, Inc., a consulting firm dedicated to improving the quality of care provided by oncologists throughout the nation.

Brian Sweet, B.S. Pharm., M.B.A., Executive Director, Healthcare Alliances, Astra Zeneca Pharmaceuticals

Brian is focused on AstraZeneca’s initiatives in real world evidence and comparative effectiveness research and collaborating with health plans, pharmacy benefit managers, and a variety of key business partners. In addition, he coordinates with managed markets customers on the development of performance-driven models, health improvement programs, value-based insurance designs, and evolving healthcare reform issues.

Brian is the former Chief Pharmacy Officer of WellPoint, Inc., a 34 million member Health Benefits Company located in Indianapolis, Indiana. Brian was responsible for overseeing all Clinical Pharmacy Services at WellPoint including leading the National Pharmacy and Therapeutics Committee, which uses integrated data analyses and total cost of care modeling to improve patient health outcomes. In addition, he oversaw the development of strategic pharmacy alliances with academia, government, health organizations, and pharmaceutical companies for the purpose of working together to promote the effective and appropriate use of drugs in the communities that WellPoint serves. Brian provided strategic leadership for establishing enterprise pharmacy programs as an integral part of the organization in developing corporate pharmacy policy and innovative pharmacy benefit designs. He was also responsible for influencing public policy by communicating with media, analysts, professional organizations, members and providers to provide: public policy, legislative, and media responses related to pharmacy coverage, benefits, medication management, the WellPoint Outcomes-Based Formulary application, and specialty pharmacy initiatives.

John Whang, MD, COO, Reimbursement Intelligence

John joined RI from McKinsey, where he was a senior consultant in its Health Care Practice, focusing on payer, provider, device and pharmaceutical clients. Before McKinsey, John was Director of Non-Invasive Cardiovascular Services at Morristown Medical Center in Morristown, NJ, which is the second largest cardiac program in the Northeast. John managed all aspects of inpatient and outpatient cardiovascular services while actively practicing cardiology. He led the introduction of cutting-edge technologies such as intra-cardiac echo (ICE) to enable the growth of innovative catheter-based programs including PFO closure and transcatheter valve. John has an AB from Harvard and an MD from Columbia University’s College of Physicians and Surgeons.

Marcus Wilson, President, Healthcore (Wellpoint Inc.)

Marcus Wilson, Pharm.D. is president of HealthCore, a wholly owned subsidiary of WellPoint, Inc. HealthCore utilizes the vast world research environment provided by WellPoint’s national reach and local depth to provide research service focused on clinical effectiveness, health economics and safety evaluation of various healthcare interventions. The results of the studies offer clarity that empowers a broad array of healthcare decision makers to act with precision to improve quality, safety and affordability.

Dr. Wilson received his doctor of pharmacy degree from VCU/Medical College of Virginia and joined the faculty of the University of Sciences in Philadelphia after completing his residency. While on the University of the Sciences in Philadelphia faculty, he developed an outcomes research and patient education division within the HealthCare Centers of Christiana, a wholly-owed division of Blue Cross Blue Shield of Delaware (BCBSD). The program assets were later purchased from BCBSD and used to found HealthCore. Much of his work has focused upon assessing the value (benefit versus cost) and safety of various healthcare products, services and programs including pharmaceuticals, biotechnologies, medical devices and disease management programs in the real world setting.

Dr Wilson serves as member of the FDA Mini-Sentinel Program’s Project Operations Council, the Brookings Active Safety Surveillance Council, the OMOP Executive Board, the eHealth Initiative Board of Directors and the Board of Visitors for the Mayes College of Healthcare Business & Policy at the University of Sciences in Philadelphia and the 2020 Vision Task Force for the ISPOR.

Steve Wooding, VP, Head of Market Access, JANSSEN EMEA, Johnson & Johnson

Steve Wooding worked as a physician in the NHS for seven years before joining Ciba-Geigy as a Medical Advisor.

He joined Janssen UK in 1992 and was involved in the development of Risperdal™ and Durogesic™ developing his expertise in both drug development and delivery systems.

Following a spell as Medical Director of Janssen South Africa from 1997 to 2000 he moved through a series of commercial sales and marketing roles in the UK and Canada before joining first Janssen Australia and then Janssen UK as Managing Director.

In October 2009, Steve was appointed Vice President Medical Affairs EMEA and in January 2011, Steve was appointed to his current role as Head of Market Access EMEA. In this role Steve leads Medical Affairs, Health Economics and Pricing, Strategic Marketing, New Business Development and Customer Orientation and Innovation groups in an integrated function. The aim is to provide rapid and sustained patient access to innovative medicines.

Donald D. Yin, Ph.D., Associate VP & Head, Global Health Outcomes, Merck & Co., Inc.

Dr. Yin is Associate Vice President at Merck and currently serves as the head of Global Health Outcomes. He has overall responsibility for leading the Global Health Outcomes organization to develop and implement health outcomes strategies and plans for all Merck products globally. His previous positions included the Executive Director of Health Economics and Outcomes Research at Forest Laboratories, head of Market Access and Public Policy at Merck in China, Executive Director of Global Market Access Strategy at Merck. He has more than 15 years of experience in health economics, outcomes research, health technology assessment, comparative effectiveness research and health services research. He has authored or co-authored more than 80 peer reviewed scientific articles and published more than 150 abstracts at national and international scientific meetings.

Before joining the pharmaceutical industry in 1996, Dr. Yin was an Assistant Professor of Health Economics at the University of Pennsylvania and a Senior Fellow at the Leonard Davis Institute of Health Economics. He received his Ph.D. from the Wharton School of the University of Pennsylvania in 1993 and a Master of Science degree from the California Institute of Technology. He received his B.S. degree in Applied Mathematics and a M.S. degree in Econometrics from the Huazhong University of Science and Technology in Wuhan, China.